Have a feature idea you'd love to see implemented?
Let us know!
LTRN Lantern Pharma Inc
Price (delayed)
$3.37
Market cap
$36.28M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.65
Enterprise value
$23.52M
Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. It leverages advances in machine learning, genomics, and artificial intelligence by
Highlights
The company's debt fell by 30% YoY but it rose by 13% QoQ
The quick ratio has plunged by 55% YoY and by 25% from the previous quarter
The equity has contracted by 36% YoY and by 14% from the previous quarter
Key stats
What are the main financial stats of LTRN
Market
Valuations
Earnings
Shares outstanding
10.76M
Market cap
$36.28M
Enterprise value
$23.52M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.17
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$17.75M
EBITDA
-$17.57M
Free cash flow
-$15.27M
Per share
Balance sheet
Liquidity
EPS
-$1.65
Free cash flow per share
-$1.42
Book value per share
$2.87
Revenue per share
$0
TBVPS
$3.31
Total assets
$35.59M
Total liabilities
$4.66M
Debt
$218,696
Equity
$30.93M
Working capital
$30.69M
Debt to equity
0.01
Current ratio
7.67
Quick ratio
7.23
Net debt/EBITDA
0.73
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-42.6%
Return on equity
-46.4%
Return on invested capital
-94.2%
Return on capital employed
-57.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LTRN stock price
How has the Lantern Pharma stock price performed over time
Intraday
-0.59%
1 week
-3.71%
1 month
-14.68%
1 year
23.9%
YTD
-21.26%
QTD
-8.17%
Financial performance
How have Lantern Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$19.54M
Net income
-$17.75M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 26% year-on-year
The company's net income fell by 24% YoY
Growth
What is Lantern Pharma's growth rate over time
Valuation
What is Lantern Pharma stock price valuation
P/E
N/A
P/B
1.17
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Lantern Pharma's EPS has decreased by 25% YoY
LTRN's price to book (P/B) is 44% lower than its 5-year quarterly average of 2.1 and 26% lower than its last 4 quarters average of 1.6
The equity has contracted by 36% YoY and by 14% from the previous quarter
Efficiency
How efficient is Lantern Pharma business performance
The ROE has plunged by 76% YoY and by 13% from the previous quarter
Lantern Pharma's return on assets has shrunk by 70% YoY and by 11% QoQ
The return on invested capital has declined by 28% year-on-year and by 3.2% since the previous quarter
Dividends
What is LTRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LTRN.
Financial health
How did Lantern Pharma financials performed over time
The current ratio has dropped by 55% year-on-year and by 23% since the previous quarter
The quick ratio has plunged by 55% YoY and by 25% from the previous quarter
The company's debt is 99% lower than its equity
The equity has contracted by 36% YoY and by 14% from the previous quarter
The company's debt fell by 30% YoY but it rose by 13% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.